Patents by Inventor PATRICK SCHÖPF

PATRICK SCHÖPF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL MOLECULE INHIBITORS OF KRAS PROTEINS
    Publication number: 20260035386
    Abstract: Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: October 9, 2025
    Publication date: February 5, 2026
    Inventors: SHUHEI KAWAMURA, YU KOBAYAKAWA, TSUYOSHI OSHIMA, TAKAO UNO, Patrick Schöpf
  • Small molecule inhibitors of KRAS proteins
    Patent number: 12466840
    Abstract: Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Grant
    Filed: October 18, 2024
    Date of Patent: November 11, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Shuhei Kawamura, Yu Kobayakawa, Tsuyoshi Oshima, Takao Uno, Patrick Schöpf
  • SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS
    Publication number: 20240317759
    Abstract: Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D and/or G12V mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 26, 2024
    Inventors: YU KOBAYAKAWA, TSUYOSHI OSHIMA, SATORU ITO, PATRICK SCHÖPF
  • SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT
    Publication number: 20240262842
    Abstract: Compounds of Formula (I) or (Ia) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or (Ia) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: April 27, 2022
    Publication date: August 8, 2024
    Inventors: Kazuaki SHIBATA, Hiroki Asakura, Kei AKEMOTO, Toshihiro SAKAMOTO, Hitomi KONDO, Tomohiro YAMAMOTO, Risako MIURA, Patrick SCHÖPF, Juan DEL POZO, George Madalin GIAMBUSU, Thomas H. GRAHAM, Yongxin HAN, Elisabeth T. HENNESSY, Anandan PALANI, Michael RYAN, David L. Sloman, Steven HOWARD
  • SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT
    Publication number: 20240239788
    Abstract: Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: April 15, 2022
    Publication date: July 18, 2024
    Inventors: David L. Sloman, Gianni Chessari, Patrick Schöpf, Steven Howard, Yuichi Kawai, Kazuaki Shibata, Hiroki Asakura, Takao Uno, Takeshi Sagara, Masayuki Nakamura, Yu Kobayakawa, David Jonathan Bennett, Indu Bharathan, Thomas H. Graham, Yongxin Han, Zahid Hussain, Xiaoshen Ma, Mihir Mandal, Ryan D. Otte, Anandan Palani, Uma Swaminathan, Mycah Uehling, Yingchun Ye, Ryan Chau, Alec H. Christian, Symon Gathiaka, Timothy J. Henderson, Elisabeth T. Hennessy, Andrew J. Hoover, Shuhei Kawamura, Igri Kolaj, Thomas W. Lyons, Matthew J. Mitcheltree, Aaron Sather
  • 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF
    Publication number: 20230023023
    Abstract: The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.
    Type: Application
    Filed: October 29, 2020
    Publication date: January 26, 2023
    Inventors: KAZUAKI SHIBATA, YUICHI KAWAI, HIROKI ASAKURA, TETSUYA SUGIMOTO, NAOKI EGASHIRA, TOMOHIRO YAMAMOTO, TATSUYA SUZUKI, YUKI KATAOKA, TAKESHI SAGARA, TOSHIHIRO SAKAMOTO, HITOMI KONDO, CHRISTOPHER CHARLES FREDERICK HAMLETT, PATRICK SCHÖPF, DAVID GEOFFREY TWIGG